Clinical trial
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
NCT00215605 · Exelixis, Industry · Completed
Key facts
| NCT number | NCT00215605 |
|---|---|
| Title | Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies |
| Official title | A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies |
| Lead sponsor | Exelixis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Cancer, Thyroid Carcinoma |
| Intervention type | Drug |
| Interventions | XL184 |
| Enrollment | 85 |
| Start date | Sep 1, 2005 |
| Primary completion | Apr 1, 2011 |
| Completion | Jul 1, 2012 |
| First posted | Sep 22, 2005 |
| Last update posted | Feb 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: